{"gene":"WFDC2","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":2014,"finding":"HE4 undergoes nuclear and nucleolar translocation upon stimulation with EGF, VEGF, and insulin, and interacts with EGFR, IGF1R, and transcription factor HIF1α. This nuclear translocation is mediated by importin-4, and ivermectin (an importin inhibitor) blocks HE4/importin-4 nuclear accumulation.","method":"Co-immunoprecipitation, nuclear fractionation, live-cell imaging, pharmacological inhibition with ivermectin","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and nuclear translocation with functional consequence shown, single lab with multiple orthogonal methods","pmids":["24389815","24975515"],"is_preprint":false},{"year":2014,"finding":"HE4 interacts with estrogen receptor-α (ER-α), and HE4 overexpression results in ER-α downregulation in vitro. 17β-estradiol, tamoxifen, and fulvestrant induce nuclear and nucleolar translocation of HE4, and HE4 overexpression induces resistance to antiestrogens.","method":"Co-immunoprecipitation, western blot, cell viability assays, immunofluorescence","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional rescue, single lab, two orthogonal methods","pmids":["24975515"],"is_preprint":false},{"year":2016,"finding":"HE4 overexpression promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells by suppressing cisplatin-mediated upregulation of EGR1 (a MAPK-regulated pro-apoptotic gene) and suppressing p38 MAPK activation. Recombinant HE4 treatment dramatically affected ERK activation. HE4 also upregulated α-tubulin and β-tubulin levels and increased MAPT gene expression. CRISPR/Cas-mediated knockdown of HE4 partially reversed chemoresistance.","method":"MTS assays, western blot, microarray, qRT-PCR, CRISPR/Cas knockdown, treatment with recombinant HE4","journal":"Journal of ovarian research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KD with functional rescue plus microarray validation, single lab, multiple orthogonal methods","pmids":["27184254"],"is_preprint":false},{"year":2019,"finding":"HE4 overexpression activates the NF-κB pathway through phosphorylation and nuclear translocation of the P65 subunit, which upregulates TIMP-1 and thereby inhibits MMP-2 activity, leading to reduced ECM degradation and renal fibrosis. Hypoxia induces HE4 expression in renal tubular epithelial cells via a HIF-1α/HE4/NF-κB signaling axis. Silencing HE4 inhibited hypoxia-induced ECM deposition and alleviated fibrosis in UUO mice in vivo.","method":"UUO mouse model, HK2 cell line overexpression/silencing, western blot, phosphorylation assay, MMP-2 activity assay, immunofluorescence","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO and in vitro mechanistic studies with pathway validation, single lab, multiple methods","pmids":["31909536"],"is_preprint":false},{"year":2020,"finding":"WFDC2 binds to the extracellular domain of EGFR (shown by co-immunoprecipitation and co-localization). Overexpression of WFDC2 or addition of recombinant HE4 inactivates the EGFR/AKT/GSK3B/Snail signaling pathway and restrains epithelial-mesenchymal transition (EMT), suppressing prostate cancer metastasis.","method":"Co-immunoprecipitation, co-localization assay, immunoblot, in vivo and in vitro metastasis assays, recombinant protein addition","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and co-localization plus functional pathway validation, single lab","pmids":["32678075"],"is_preprint":false},{"year":2019,"finding":"WFDC2 contributes to ovarian cancer EMT by activating the AKT signaling pathway and inducing MMP-2 expression. Knockdown of WFDC2 suppresses EMT (upregulation of E-cadherin, downregulation of Vimentin) and decreases MMP-2. The EMT phenotype and invasion induced by WFDC2 overexpression can be reversed by siMMP-2 and PI3K/AKT signaling inhibitor.","method":"siRNA knockdown, overexpression constructs, western blot, in vivo xenograft, PI3K/AKT inhibitor rescue","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD/OE with pharmacological rescue, single lab, multiple orthogonal methods","pmids":["31118763"],"is_preprint":false},{"year":2019,"finding":"Knockdown of HE4 inhibits the JAK/STAT3 pathway in ovarian cancer cells, suppressing proliferation, invasion, and migration, and reducing MMP-2/MMP-9 levels and EMT markers in vitro and in vivo.","method":"siRNA knockdown, western blot, flow cytometry, xenograft model","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with defined pathway readout in vitro and in vivo, single lab","pmids":["31477564"],"is_preprint":false},{"year":2019,"finding":"HE4 forms a triple protein complex with ANXA2 (Annexin A2) and MMP2, co-localizing in the cytoplasm and membrane. HE4 mediates MMP2 expression via ANXA2 (acting as a 'bridge') to promote cancer cell migration.","method":"Co-immunoprecipitation, double-labeling immunofluorescence, Transwell assay, scratch test","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus co-localization showing ternary complex, single lab","pmids":["31210752"],"is_preprint":false},{"year":2020,"finding":"HE4 activates STAT3 signaling and promotes upregulation of pro-angiogenic STAT3 target genes IL8 and HIF1A in immune cells, ovarian cancer cells, and endothelial cells. HE4 promoted tube formation in an in vitro angiogenesis model in a STAT3-dependent manner.","method":"Gene expression analysis, in vitro tube formation assay, western blot, STAT3 pathway inhibition, patient sample correlation","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional angiogenesis assay with STAT3 pathway validation, single lab, multiple orthogonal methods","pmids":["32444701"],"is_preprint":false},{"year":2021,"finding":"HE4 promotes PD-L1 expression in tumor cells and macrophages through a novel posttranscriptional mechanism; high tumoral HE4 promotes an ascites cytokine profile rich in myeloid-recruiting factors, influx of M2 macrophages, increased arginase 1, and reduced CTL activation and NK cell recruitment.","method":"Syngeneic rat tumor model with HE4 high/low cancer cells, cytokine profiling, flow cytometry, retrospective patient sample analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo syngeneic model plus patient sample correlation, single lab","pmids":["33903172"],"is_preprint":false},{"year":2021,"finding":"WFDC2 promotes spasmolytic polypeptide-expressing metaplasia (SPEM) in mouse stomach by upregulating IL-33 expression in injured mucosa, which induces M2 macrophage polarization. Wfdc2-knockout mice are resistant to SPEM development. Supplementation of recombinant WFDC2 induces IL-33 production and SPEM.","method":"Wfdc2-knockout mice, three SPEM induction models (DMP-777, L635, tamoxifen), transcriptomic analysis, recombinant WFDC2 supplementation","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO replicated across three independent SPEM models plus recombinant protein rescue, single lab with multiple orthogonal methods","pmids":["34116028"],"is_preprint":false},{"year":2019,"finding":"WFDC2 (Wfdc2) knockout mice die neonatally from respiratory failure due to increased apoptosis in type-I alveolar cells, causing hypovascular lung tissue and severe dyspnea. Wfdc2 is required for normal lung organogenesis.","method":"TALEN-based gene deletion in mice, histopathology, apoptosis assays on lung tissue","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with specific cellular phenotype (type-I alveolar apoptosis), single lab","pmids":["31780266"],"is_preprint":false},{"year":2019,"finding":"Wfdc2-null mice display progressive atelectasis at birth with impaired cilia, absence of mature club cells from tracheo-bronchial airways, and malformed lamellar bodies in type II alveolar epithelial cells. RNA sequencing shows significant activation of a pro-inflammatory pathway in mutant lungs.","method":"Wfdc2-GFP knock-in and null-mutant mouse lines, histopathology, RNA sequencing, immunofluorescence","journal":"Disease models & mechanisms","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic null mice with multiple defined cellular phenotypes and transcriptomic validation, independently generated mouse line from separate lab","pmids":["31562139"],"is_preprint":false},{"year":2024,"finding":"Biallelic pathogenic variants in WFDC2 cause nasal polyposis and bronchiectasis in humans. WFDC2 is expressed in secretory cells of airway epithelium and submucosal glands. A founder variant p.Cys49Arg structurally hampers glycosylation and thereby blocks secretion of mature WFDC2, confirming that secretion is required for normal airway function.","method":"Next-generation and Sanger sequencing, Western blotting, immunofluorescence microscopy, deglycosylation assays, computer simulations of protein structure, electrochemiluminescence immunoassay of serum","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — human genetic disease identified in 10 unrelated families with biochemical confirmation of glycosylation/secretion defect by deglycosylation assay and structural modeling","pmids":["38626355"],"is_preprint":false},{"year":2021,"finding":"CFTR dysfunction contributes to elevated HE4 expression via the NF-κB pathway in cystic fibrosis bronchial epithelial cells. CFTR modulators (lumacaftor/ivacaftor, tezacaftor/ivacaftor) partially restored CFTR activity and reduced HE4 secretion. TNF-α upregulated HE4 through NF-κB (p65 nuclear translocation), and NF-κB inhibitor BAY 11-7082 suppressed HE4 expression.","method":"CFBE cell line transfected with F508del-CFTR or wt-CFTR, whole-cell patch-clamp, immunoassay, fluorescence microscopy for p65 translocation, pharmacological inhibition","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patch-clamp-validated CFTR modulation correlated with HE4 expression plus NF-κB pathway mechanistic validation, single lab","pmids":["34054511"],"is_preprint":false},{"year":2019,"finding":"HDAC3 interacts with HE4 protein (identified as an HDAC3-interacting protein). HDAC3 promotes ovarian carcinoma cell proliferation, invasion, and migration by increasing HE4 expression, and this axis activates the PI3K/AKT signaling pathway (elevated P-PI3K and P-AKT).","method":"Co-immunoprecipitation (HDAC3-HE4 interaction), immunohistochemistry, western blot, wound healing assay, Transwell assay, CCK8 proliferation assay, siRNA knockdown","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP for interaction, functional assays show PI3K/AKT pathway activation, single lab","pmids":["31302139"],"is_preprint":false},{"year":2018,"finding":"HE4 suppresses osteopontin (OPN) expression in peripheral blood mononuclear cells (PBMCs) and compromises their cytotoxicity against ovarian cancer cells. SKOV3 and OVCAR8 cells showed enhanced proliferation in conditioned media from HE4-exposed PBMCs, an effect attenuated by recombinant OPN or OPN-inducible cytokines (IL-12 and IFN-γ). HE4-silenced SKOV3 cells were more susceptible to cytotoxic cell death upon co-culture with PBMCs.","method":"Subtractive hybridization, PBMC co-culture, conditioned media experiments, recombinant OPN rescue, siRNA knockdown of HE4, patient biopsy correlation","journal":"Clinical and experimental immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene expression profiling with functional rescue and KD validation, single lab, multiple methods","pmids":["29745428"],"is_preprint":false},{"year":2013,"finding":"HE4 overexpression in endometrial cancer cell lines significantly enhanced cell proliferation, matrigel invasion, and colony formation in soft agar, and promoted tumor growth in a mouse xenograft model, establishing a direct role for HE4 in tumor progression.","method":"Stable transfection of HE4-V0 expression construct, cell proliferation assay, matrigel invasion assay, soft agar colony formation, mouse xenograft model","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable overexpression with in vivo xenograft validation, single lab, multiple orthogonal cellular assays","pmids":["23502467"],"is_preprint":false},{"year":2014,"finding":"Recombinant extracellular HE4 protein promotes proliferation of pancreatic and endometrial cancer cell lines, increases DNA synthesis, and modulates cell cycle markers PCNA (upregulated) and p21 (downregulated) at mRNA and protein levels.","method":"Cell viability assay (CCK-8), BrdU incorporation, western blot, qRT-PCR with purified recombinant HE4 protein","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — recombinant protein treatment with defined molecular readouts, single lab, multiple orthogonal methods","pmids":["25354091"],"is_preprint":false},{"year":2021,"finding":"HE4 secreted from HE4-transfected HEK293T cells activates ERK signaling in cardiac fibroblasts and promotes their transdifferentiation, increasing expression of fibrosis-related genes. Treatment with an ERK upstream inhibitor or a neutralizing HE4 antibody canceled the profibrotic properties of HE4.","method":"HEK293T transfection, conditioned media treatment of rat neonatal cardiac fibroblasts, western blot for ERK signaling, fibrosis gene expression, neutralizing antibody rescue","journal":"Journal of the American Heart Association","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditioned media experiment with pathway rescue by neutralizing antibody and inhibitor, single lab","pmids":["34320813"],"is_preprint":false},{"year":2016,"finding":"High-dose estradiol (E2) increases WFDC2 expression in estrogen-sensitive HO8910 ovarian cancer cells, but not in estrogen-insensitive SKOV3 cells. Knockdown of WFDC2 in SKOV3 cells confers estrogen responsiveness (proliferative response to E2), accompanied by upregulation of estrogen receptor beta (ERβ).","method":"RT-PCR, western blot, MTT proliferation assay, flow cytometry for ER expression, annexin V/PI apoptosis assay, antibody array","journal":"Journal of ovarian research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD functional rescue plus multi-method characterization, single lab","pmids":["26928556"],"is_preprint":false},{"year":2011,"finding":"In tammar wallaby, WFDC2 protein (comprising two 4-DSC domains: domain III at N-terminus and domain II at C-terminus) demonstrates antibacterial activity against Staphylococcus aureus, Salmonella enterica, and Pseudomonas aeruginosa, with this activity residing specifically in domain II. No antibacterial activity was detected against Enterococcus faecalis.","method":"Recombinant protein expression, antibacterial activity assays with individual domains, gene expression profiling during lactation","journal":"Developmental and comparative immunology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro biochemical activity assay with domain mapping, single lab, marsupial ortholog","pmids":["22024352"],"is_preprint":false},{"year":2005,"finding":"HE4 is a secreted glycoprotein; conditioned media from ovarian cancer cell lines that endogenously overexpress HE4 revealed a secreted, N-glycosylated form of the protein.","method":"RT-PCR identification of HE4-expressing cell lines, conditioned medium analysis, N-glycosylation characterization","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical characterization of secreted glycoprotein, replicated across multiple groups","pmids":["15781627"],"is_preprint":false}],"current_model":"WFDC2/HE4 is a small, secreted, N-glycosylated WAP-domain protein that functions extracellularly and, following nuclear translocation via importin-4, intracellularly: it binds EGFR's extracellular domain and ER-α, activates downstream EGFR/AKT/GSK3B/Snail and PI3K/AKT/MMP-2 signaling to promote EMT and metastasis, activates STAT3 to drive pro-angiogenic and immunosuppressive gene programs, suppresses p38/MAPK-mediated apoptotic signaling to confer chemoresistance, activates NF-κB (via p65 phosphorylation and nuclear translocation) to promote fibrosis and ECM accumulation, forms a ternary complex with ANXA2 and MMP-2 to facilitate cell migration, and in the lung is essential for neonatal alveolar function (type-I alveolar cell survival, club cell maturation, and lamellar body formation), with loss-of-function mutations in humans causing bronchiectasis and nasal polyposis due to impaired glycosylation and secretion of the mature protein."},"narrative":{"mechanistic_narrative":"WFDC2 (HE4) is a small, secreted, N-glycosylated WAP-domain protein that acts as an extracellular signaling ligand controlling epithelial homeostasis, tissue remodeling, and tumor progression [PMID:15781627, PMID:32678075]. Its biology centers on engagement of cell-surface receptors and activation of downstream signaling: WFDC2 binds the extracellular domain of EGFR and, depending on context, modulates EGFR/AKT/GSK3B/Snail signaling and epithelial-mesenchymal transition [PMID:32678075], while in ovarian cancer it drives EMT and invasion through PI3K/AKT-dependent induction of MMP-2 [PMID:31118763] and activation of JAK/STAT3 signaling [PMID:31477564]. WFDC2 also forms a cytoplasmic and membrane-associated ternary complex with ANXA2 and MMP-2, using ANXA2 as a bridge to promote migration [PMID:31210752]. Beyond canonical surface signaling, WFDC2 undergoes importin-4-mediated nuclear and nucleolar translocation upon EGF, VEGF, insulin, or estrogen stimulation and interacts with EGFR, IGF1R, HIF1α, and ER-α [PMID:24389815, PMID:24975515]. WFDC2 shapes the tumor and tissue microenvironment by activating STAT3 to induce pro-angiogenic genes (IL8, HIF1A) [PMID:32444701] and by fostering immunosuppression through PD-L1 induction, M2 macrophage recruitment, and suppression of cytotoxic lymphocyte activity [PMID:33903172, PMID:29745428]. A recurring fibrotic and inflammatory axis operates through NF-κB: WFDC2 activates p65 phosphorylation and nuclear translocation to drive ECM accumulation and renal fibrosis via TIMP-1/MMP-2 [PMID:31909536], promotes IL-33-dependent gastric metaplasia and M2 polarization [PMID:34116028], and is itself induced by TNF-α and CFTR dysfunction through NF-κB [PMID:34054511]. In vivo, Wfdc2 is essential for neonatal lung function: knockout mice die from respiratory failure with type-I alveolar cell apoptosis, absent mature club cells, malformed lamellar bodies, and aberrant pro-inflammatory activation [PMID:31780266, PMID:31562139]. Biallelic loss-of-function variants in WFDC2 cause human nasal polyposis and bronchiectasis, with a founder p.Cys49Arg substitution that disrupts glycosylation and blocks secretion of the mature protein, establishing that secretion is required for normal airway function [PMID:38626355].","teleology":[{"year":2005,"claim":"Established the basic biochemical identity of HE4 as a secreted, N-glycosylated protein, defining it as an extracellular factor rather than an intracellular enzyme.","evidence":"Conditioned-medium analysis and N-glycosylation characterization from HE4-overexpressing ovarian cancer lines","pmids":["15781627"],"confidence":"Medium","gaps":["No receptor or binding partner identified","Function of the secreted protein not addressed"]},{"year":2013,"claim":"Showed that HE4 is not merely a biomarker but a direct driver of tumor progression, motivating mechanistic dissection of its signaling.","evidence":"Stable HE4 overexpression with proliferation, invasion, soft-agar colony and xenograft assays in endometrial cancer cells","pmids":["23502467"],"confidence":"Medium","gaps":["Receptor and downstream pathway unresolved","Single tumor type"]},{"year":2014,"claim":"Revealed an unexpected intracellular dimension by showing growth-factor- and estrogen-stimulated importin-4-dependent nuclear/nucleolar translocation and interactions with EGFR, IGF1R, HIF1α and ER-α, plus a role in antiestrogen resistance.","evidence":"Co-IP, nuclear fractionation, live-cell imaging, ivermectin inhibition, and viability assays in cancer cells","pmids":["24389815","24975515"],"confidence":"Medium","gaps":["Nuclear function of HE4 (transcriptional or otherwise) not defined","Direct vs. indirect nature of receptor interactions unclear"]},{"year":2014,"claim":"Demonstrated that extracellular recombinant HE4 alone is mitogenic and modulates cell-cycle regulators, confirming a ligand-like proliferative activity.","evidence":"Recombinant HE4 treatment with BrdU, CCK-8, and PCNA/p21 readouts in pancreatic and endometrial lines","pmids":["25354091"],"confidence":"Medium","gaps":["Receptor mediating the proliferative effect not identified","Signaling cascade not mapped"]},{"year":2016,"claim":"Linked HE4 to chemoresistance by showing it suppresses p38/ERK-MAPK pro-apoptotic signaling and the pro-apoptotic gene EGR1.","evidence":"Recombinant HE4 and CRISPR knockdown with MTS, microarray, and western blot in ovarian cancer cells","pmids":["27184254"],"confidence":"Medium","gaps":["Direct molecular target upstream of MAPK not defined","Tubulin/MAPT effects mechanistically unexplained"]},{"year":2019,"claim":"Assembled a coherent pro-metastatic signaling network, defining PI3K/AKT-MMP-2-driven EMT, JAK/STAT3 activation, an HDAC3-HE4-PI3K/AKT axis, and an ANXA2-MMP-2 ternary complex.","evidence":"siRNA/overexpression with pharmacological rescue, Co-IP, immunofluorescence, and xenografts across ovarian cancer studies","pmids":["31118763","31477564","31302139","31210752"],"confidence":"Medium","gaps":["Whether AKT and STAT3 arms are parallel or sequential is unresolved","Direct receptor for HE4 in these pathways not pinpointed","ANXA2 interaction shown by single-lab Co-IP"]},{"year":2019,"claim":"Established WFDC2 as essential for neonatal lung development, providing the first in vivo loss-of-function phenotype and shifting the picture from cancer ligand to developmental regulator.","evidence":"TALEN and null/GFP knock-in mouse lines from independent labs with histopathology, apoptosis assays, and RNA-seq","pmids":["31780266","31562139"],"confidence":"High","gaps":["Molecular mechanism connecting WFDC2 loss to alveolar/club-cell defects not defined","Receptor mediating the developmental role unknown"]},{"year":2019,"claim":"Identified an NF-κB/TIMP-1/MMP-2 axis driving fibrosis, showing HE4 restrains ECM degradation downstream of HIF-1α.","evidence":"UUO mouse model and HK2 overexpression/silencing with phosphorylation and MMP-2 activity assays","pmids":["31909536"],"confidence":"Medium","gaps":["How secreted HE4 activates intracellular NF-κB is unresolved","Receptor not identified"]},{"year":2020,"claim":"Provided reciprocal evidence that WFDC2 binds the EGFR extracellular domain and, in prostate cancer, can suppress EGFR/AKT/GSK3B/Snail-driven EMT, indicating context-dependent (suppressive vs. promoting) outputs.","evidence":"Reciprocal Co-IP, co-localization, recombinant protein, and metastasis assays in prostate cancer","pmids":["32678075"],"confidence":"Medium","gaps":["Reason for opposite EMT outcomes between tumor types unexplained","Stoichiometry and affinity of EGFR binding not determined"]},{"year":2020,"claim":"Extended HE4 function to the microenvironment by showing STAT3-dependent induction of pro-angiogenic IL8 and HIF1A and promotion of endothelial tube formation.","evidence":"Gene expression, tube-formation assay, STAT3 inhibition, and patient correlation","pmids":["32444701"],"confidence":"Medium","gaps":["Receptor coupling HE4 to STAT3 not defined","In vivo angiogenic contribution not directly tested"]},{"year":2021,"claim":"Defined HE4 as an immunosuppressive factor, inducing PD-L1, recruiting M2 macrophages, and dampening cytotoxic lymphocyte activity, partly via suppression of osteopontin.","evidence":"Syngeneic rat tumor model, cytokine profiling, flow cytometry, PBMC co-culture with OPN rescue, and patient samples","pmids":["33903172","29745428"],"confidence":"Medium","gaps":["Posttranscriptional mechanism of PD-L1 induction undefined","Direct vs. indirect action on immune cells unclear"]},{"year":2021,"claim":"Broadened the inflammatory/fibrotic role across organs, showing WFDC2 drives IL-33-dependent gastric metaplasia, ERK-dependent cardiac fibroblast transdifferentiation, and is induced by CFTR dysfunction via NF-κB.","evidence":"Wfdc2-knockout mice with three SPEM models and recombinant rescue, conditioned-media cardiac fibroblast assays with neutralizing antibody, and CFBE patch-clamp/NF-κB studies","pmids":["34116028","34320813","34054511"],"confidence":"Medium","gaps":["Receptor transducing the profibrotic/metaplastic signal not identified","Whether NF-κB induction of HE4 and HE4 activation of NF-κB form a feedback loop is untested"]},{"year":2024,"claim":"Connected WFDC2 to a human Mendelian disease, showing biallelic loss-of-function causes nasal polyposis and bronchiectasis through a glycosylation/secretion defect, validating that mature secreted protein is required for airway function.","evidence":"Sequencing in 10 families, deglycosylation assays, western blot, immunofluorescence, and structural modeling of the p.Cys49Arg founder variant","pmids":["38626355"],"confidence":"High","gaps":["Molecular target of secreted WFDC2 in the airway not identified","How loss leads to polyposis vs. bronchiectasis not dissected"]},{"year":null,"claim":"The central unresolved question is the identity and stoichiometry of the bona fide WFDC2 receptor(s) that transduce its many context-dependent outputs (EGFR/AKT, STAT3, NF-κB, ERK), and the molecular basis of its opposite roles across tissues and tumor types.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying receptor model across the documented pathways","Mechanism reconciling tumor-promoting and tumor-suppressing EMT effects unknown","Biochemical function of nuclear-localized WFDC2 undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[4,18,5,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,3,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[22,13]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[7]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,6,8,3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,3,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,10,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,12]}],"complexes":["WFDC2-ANXA2-MMP2 ternary complex"],"partners":["EGFR","IGF1R","HIF1A","ESR1","ANXA2","MMP2","HDAC3","IPO4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14508","full_name":"WAP four-disulfide core domain protein 2","aliases":["Epididymal secretory protein E4","Major epididymis-specific protein E4","Putative protease inhibitor WAP5"],"length_aa":124,"mass_kda":13.0,"function":"Broad range protease inhibitor","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q14508/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/WFDC2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/WFDC2","total_profiled":1310},"omim":[{"mim_id":"620984","title":"BRONCHIECTASIS AND NASAL POLYPOSIS; BENP","url":"https://www.omim.org/entry/620984"},{"mim_id":"619430","title":"SERINE PEPTIDASE INHIBITOR, KUNITZ-TYPE, 4; SPINT4","url":"https://www.omim.org/entry/619430"},{"mim_id":"617548","title":"WAP 4-DISULFIDE CORE DOMAIN 2; WFDC2","url":"https://www.omim.org/entry/617548"},{"mim_id":"613941","title":"SERINE PEPTIDASE INHIBITOR, KUNITZ-TYPE, 3; SPINT3","url":"https://www.omim.org/entry/613941"},{"mim_id":"266600","title":"INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 1; IBD1","url":"https://www.omim.org/entry/266600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"cervix","ntpm":4905.6},{"tissue":"salivary gland","ntpm":1869.1}],"url":"https://www.proteinatlas.org/search/WFDC2"},"hgnc":{"alias_symbol":["HE4","WAP5","dJ461P17.6","EDDM4"],"prev_symbol":[]},"alphafold":{"accession":"Q14508","domains":[{"cath_id":"4.10.75.10","chopping":"32-75","consensus_level":"medium","plddt":92.7423,"start":32,"end":75},{"cath_id":"4.10.75.10","chopping":"78-124","consensus_level":"medium","plddt":86.2374,"start":78,"end":124}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14508","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14508-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14508-F1-predicted_aligned_error_v6.png","plddt_mean":82.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=WFDC2","jax_strain_url":"https://www.jax.org/strain/search?query=WFDC2"},"sequence":{"accession":"Q14508","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14508.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14508/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14508"}},"corpus_meta":[{"pmid":"12839961","id":"PMC_12839961","title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12839961","citation_count":552,"is_preprint":false},{"pmid":"15781627","id":"PMC_15781627","title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15781627","citation_count":433,"is_preprint":false},{"pmid":"16607372","id":"PMC_16607372","title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16607372","citation_count":327,"is_preprint":false},{"pmid":"19337252","id":"PMC_19337252","title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19337252","citation_count":221,"is_preprint":false},{"pmid":"16600032","id":"PMC_16600032","title":"WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung.","date":"2006","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/16600032","citation_count":165,"is_preprint":false},{"pmid":"19732003","id":"PMC_19732003","title":"HE4 as a biomarker for ovarian and endometrial cancer management.","date":"2009","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/19732003","citation_count":121,"is_preprint":false},{"pmid":"22301440","id":"PMC_22301440","title":"Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.","date":"2011","source":"American journal of obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/22301440","citation_count":112,"is_preprint":false},{"pmid":"24627132","id":"PMC_24627132","title":"Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24627132","citation_count":98,"is_preprint":false},{"pmid":"23093276","id":"PMC_23093276","title":"Human epididymis protein 4 (HE4) in benign and malignant diseases.","date":"2012","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23093276","citation_count":74,"is_preprint":false},{"pmid":"24389815","id":"PMC_24389815","title":"HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24389815","citation_count":69,"is_preprint":false},{"pmid":"25169975","id":"PMC_25169975","title":"HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review.","date":"2014","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25169975","citation_count":67,"is_preprint":false},{"pmid":"27347403","id":"PMC_27347403","title":"The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer.","date":"2016","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/27347403","citation_count":62,"is_preprint":false},{"pmid":"34638250","id":"PMC_34638250","title":"HE4 as a Biomarker for Endometrial Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34638250","citation_count":61,"is_preprint":false},{"pmid":"23502467","id":"PMC_23502467","title":"HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23502467","citation_count":61,"is_preprint":false},{"pmid":"23891789","id":"PMC_23891789","title":"Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.","date":"2013","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23891789","citation_count":59,"is_preprint":false},{"pmid":"22126021","id":"PMC_22126021","title":"HE4 in ovarian cancer: from discovery to clinical application.","date":"2011","source":"Advances in clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22126021","citation_count":57,"is_preprint":false},{"pmid":"35383661","id":"PMC_35383661","title":"Dapagliflozin Attenuates Contrast-induced Acute Kidney Injury by Regulating the HIF-1α/HE4/NF-κB Pathway.","date":"2022","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35383661","citation_count":57,"is_preprint":false},{"pmid":"27184254","id":"PMC_27184254","title":"HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.","date":"2016","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/27184254","citation_count":55,"is_preprint":false},{"pmid":"23909069","id":"PMC_23909069","title":"The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.","date":"2013","source":"Oncology (Williston Park, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23909069","citation_count":55,"is_preprint":false},{"pmid":"22854652","id":"PMC_22854652","title":"Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis.","date":"2012","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/22854652","citation_count":54,"is_preprint":false},{"pmid":"31909536","id":"PMC_31909536","title":"Hypoxia-induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF-κB.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31909536","citation_count":52,"is_preprint":false},{"pmid":"22962406","id":"PMC_22962406","title":"Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.","date":"2012","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22962406","citation_count":45,"is_preprint":false},{"pmid":"24771264","id":"PMC_24771264","title":"HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24771264","citation_count":42,"is_preprint":false},{"pmid":"30017407","id":"PMC_30017407","title":"Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.","date":"2018","source":"Current problems in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30017407","citation_count":42,"is_preprint":false},{"pmid":"24068567","id":"PMC_24068567","title":"A critical review on HE4 performance in endometrial cancer: where are we now?","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24068567","citation_count":41,"is_preprint":false},{"pmid":"22868811","id":"PMC_22868811","title":"Diagnostic value of HE4 for ovarian cancer: a meta-analysis.","date":"2012","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22868811","citation_count":41,"is_preprint":false},{"pmid":"34116028","id":"PMC_34116028","title":"WFDC2 Promotes Spasmolytic Polypeptide-Expressing Metaplasia Through the Up-Regulation of IL33 in Response to Injury.","date":"2021","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/34116028","citation_count":40,"is_preprint":false},{"pmid":"37445657","id":"PMC_37445657","title":"Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37445657","citation_count":40,"is_preprint":false},{"pmid":"25190018","id":"PMC_25190018","title":"Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25190018","citation_count":40,"is_preprint":false},{"pmid":"26575020","id":"PMC_26575020","title":"Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26575020","citation_count":38,"is_preprint":false},{"pmid":"32359161","id":"PMC_32359161","title":"Use of a human embryonic stem cell model to discover GABRP, WFDC2, VTCN1 and ACTC1 as markers of early first trimester human trophoblast.","date":"2020","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/32359161","citation_count":37,"is_preprint":false},{"pmid":"36867090","id":"PMC_36867090","title":"Simultaneous Detection of Ovarian Cancer-Concerned HE4 and CA125 Markers Based on Cu Single-Atom-Triggered CdS QDs and Eu MOF@Isoluminol ECL.","date":"2023","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36867090","citation_count":36,"is_preprint":false},{"pmid":"32678075","id":"PMC_32678075","title":"WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32678075","citation_count":35,"is_preprint":false},{"pmid":"30317143","id":"PMC_30317143","title":"Diagnostic value of HE4 in ovarian cancer: A meta-analysis.","date":"2018","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/30317143","citation_count":34,"is_preprint":false},{"pmid":"23093277","id":"PMC_23093277","title":"HE4 in gynecological cancers: report of a European investigators and experts meeting.","date":"2012","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23093277","citation_count":34,"is_preprint":false},{"pmid":"26539494","id":"PMC_26539494","title":"Expression of HE4 in Endometrial Cancer and Its Clinical Significance.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/26539494","citation_count":33,"is_preprint":false},{"pmid":"25866324","id":"PMC_25866324","title":"Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.","date":"2015","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25866324","citation_count":33,"is_preprint":false},{"pmid":"34320813","id":"PMC_34320813","title":"HE4 Predicts Progressive Fibrosis and Cardiovascular Events in Patients With Dilated Cardiomyopathy.","date":"2021","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/34320813","citation_count":31,"is_preprint":false},{"pmid":"25127713","id":"PMC_25127713","title":"Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25127713","citation_count":30,"is_preprint":false},{"pmid":"24252907","id":"PMC_24252907","title":"HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24252907","citation_count":29,"is_preprint":false},{"pmid":"33388311","id":"PMC_33388311","title":"Endometrial cancer: A systematic review of HE4, REM and REM-B.","date":"2020","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33388311","citation_count":28,"is_preprint":false},{"pmid":"27160726","id":"PMC_27160726","title":"CA125 and HE4: Measurement Tools for Ovarian Cancer.","date":"2016","source":"Gynecologic and obstetric investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27160726","citation_count":28,"is_preprint":false},{"pmid":"29609043","id":"PMC_29609043","title":"Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.","date":"2018","source":"Journal of gynecology obstetrics and human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/29609043","citation_count":28,"is_preprint":false},{"pmid":"24975515","id":"PMC_24975515","title":"HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24975515","citation_count":27,"is_preprint":false},{"pmid":"25354091","id":"PMC_25354091","title":"Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25354091","citation_count":27,"is_preprint":false},{"pmid":"28499820","id":"PMC_28499820","title":"HE4 expression in lung cancer, a meta-analysis.","date":"2017","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28499820","citation_count":26,"is_preprint":false},{"pmid":"32444701","id":"PMC_32444701","title":"The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32444701","citation_count":26,"is_preprint":false},{"pmid":"30109256","id":"PMC_30109256","title":"Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam.","date":"2018","source":"Gynecologic oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30109256","citation_count":26,"is_preprint":false},{"pmid":"30670303","id":"PMC_30670303","title":"Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.","date":"2019","source":"Current problems in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30670303","citation_count":26,"is_preprint":false},{"pmid":"25642754","id":"PMC_25642754","title":"Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25642754","citation_count":25,"is_preprint":false},{"pmid":"27784171","id":"PMC_27784171","title":"Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.","date":"2016","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/27784171","citation_count":25,"is_preprint":false},{"pmid":"36721112","id":"PMC_36721112","title":"Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36721112","citation_count":23,"is_preprint":false},{"pmid":"36189508","id":"PMC_36189508","title":"HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer.","date":"2022","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36189508","citation_count":23,"is_preprint":false},{"pmid":"22117965","id":"PMC_22117965","title":"The role of HE4 in ovarian cancer: inhibiting tumour cell proliferation and metastasis.","date":"2011","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/22117965","citation_count":22,"is_preprint":false},{"pmid":"31477564","id":"PMC_31477564","title":"Knockdown of HE4 suppresses aggressive cell growth and malignant progression of ovarian cancer by inhibiting the JAK/STAT3 pathway.","date":"2019","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/31477564","citation_count":22,"is_preprint":false},{"pmid":"26497244","id":"PMC_26497244","title":"Recombinant HE4 protein promotes proliferation of pancreatic and endometrial cancer cell lines.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26497244","citation_count":21,"is_preprint":false},{"pmid":"22024352","id":"PMC_22024352","title":"WFDC2 is differentially expressed in the mammary gland of the tammar wallaby and provides immune protection to the mammary gland and the developing pouch young.","date":"2011","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22024352","citation_count":21,"is_preprint":false},{"pmid":"34212386","id":"PMC_34212386","title":"The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.","date":"2021","source":"Acta obstetricia et gynecologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/34212386","citation_count":21,"is_preprint":false},{"pmid":"33903172","id":"PMC_33903172","title":"HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/33903172","citation_count":21,"is_preprint":false},{"pmid":"28352780","id":"PMC_28352780","title":"The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer.","date":"2016","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/28352780","citation_count":21,"is_preprint":false},{"pmid":"31118763","id":"PMC_31118763","title":"WFDC2 contributes to epithelial-mesenchymal transition (EMT) by activating AKT signaling pathway and regulating MMP-2 expression.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31118763","citation_count":20,"is_preprint":false},{"pmid":"34737393","id":"PMC_34737393","title":"Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34737393","citation_count":20,"is_preprint":false},{"pmid":"32963750","id":"PMC_32963750","title":"Increased levels of HE4 (WFDC2) in systemic sclerosis: a novel biomarker reflecting interstitial lung disease severity?","date":"2020","source":"Therapeutic advances in chronic disease","url":"https://pubmed.ncbi.nlm.nih.gov/32963750","citation_count":20,"is_preprint":false},{"pmid":"24323399","id":"PMC_24323399","title":"HE4 combined with CA125: favorable screening tool for ovarian cancer.","date":"2013","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24323399","citation_count":19,"is_preprint":false},{"pmid":"35035759","id":"PMC_35035759","title":"Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model.","date":"2021","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/35035759","citation_count":19,"is_preprint":false},{"pmid":"31574828","id":"PMC_31574828","title":"HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31574828","citation_count":18,"is_preprint":false},{"pmid":"36900385","id":"PMC_36900385","title":"A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36900385","citation_count":18,"is_preprint":false},{"pmid":"31210752","id":"PMC_31210752","title":"Interaction of HE4 and ANXA2 exists in various malignant cells-HE4-ANXA2-MMP2 protein complex promotes cell migration.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31210752","citation_count":18,"is_preprint":false},{"pmid":"25051914","id":"PMC_25051914","title":"Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25051914","citation_count":18,"is_preprint":false},{"pmid":"26172511","id":"PMC_26172511","title":"HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.","date":"2015","source":"The Australian & New Zealand journal of obstetrics & gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/26172511","citation_count":18,"is_preprint":false},{"pmid":"31780266","id":"PMC_31780266","title":"WFDC2 gene deletion in mouse led to severe dyspnea and type-I alveolar cell apoptosis.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31780266","citation_count":16,"is_preprint":false},{"pmid":"34054511","id":"PMC_34054511","title":"Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34054511","citation_count":16,"is_preprint":false},{"pmid":"37140852","id":"PMC_37140852","title":"Point-of-care testing: a disposable label-free electrochemical CA125 and HE4 immunosensors for early detection of ovarian cancer.","date":"2023","source":"Biomedical microdevices","url":"https://pubmed.ncbi.nlm.nih.gov/37140852","citation_count":16,"is_preprint":false},{"pmid":"38626355","id":"PMC_38626355","title":"Recessively Inherited Deficiency of Secreted WFDC2 (HE4) Causes Nasal Polyposis and Bronchiectasis.","date":"2024","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38626355","citation_count":15,"is_preprint":false},{"pmid":"33285710","id":"PMC_33285710","title":"Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer.","date":"2020","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33285710","citation_count":15,"is_preprint":false},{"pmid":"31302139","id":"PMC_31302139","title":"HDAC3 positively regulates HE4 expression to promote ovarian carcinoma progression.","date":"2019","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/31302139","citation_count":14,"is_preprint":false},{"pmid":"35884367","id":"PMC_35884367","title":"Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35884367","citation_count":14,"is_preprint":false},{"pmid":"31165362","id":"PMC_31165362","title":"Human epididymis protein 4 (HE4) protects against cystic pulmonary fibrosis associated-inflammation through inhibition of NF-κB and MAPK singnaling.","date":"2019","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31165362","citation_count":14,"is_preprint":false},{"pmid":"26770527","id":"PMC_26770527","title":"Value of serum marker HE4 in pulmonary carcinoma diagnosis.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26770527","citation_count":14,"is_preprint":false},{"pmid":"28164590","id":"PMC_28164590","title":"Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.","date":"2016","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/28164590","citation_count":13,"is_preprint":false},{"pmid":"32711295","id":"PMC_32711295","title":"Meta-analysis of the diagnostic accuracy of HE4 for endometrial carcinoma.","date":"2020","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/32711295","citation_count":12,"is_preprint":false},{"pmid":"36415437","id":"PMC_36415437","title":"The Diagnostic Accuracy of Serum and Urine Human Epididymis Protein 4 (HE4) in Ovarian Cancer in 15,394 Subjects: An Updated Meta-Analysis.","date":"2022","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/36415437","citation_count":12,"is_preprint":false},{"pmid":"31562139","id":"PMC_31562139","title":"Lack of whey acidic protein (WAP) four-disulfide core domain protease inhibitor 2 (WFDC2) causes neonatal death from respiratory failure in mice.","date":"2019","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31562139","citation_count":12,"is_preprint":false},{"pmid":"33435590","id":"PMC_33435590","title":"Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/33435590","citation_count":12,"is_preprint":false},{"pmid":"28271686","id":"PMC_28271686","title":"Evaluation of HE4 in the Diagnosis and Follow Up of Non-Small Cell Lung Cancers.","date":"2017","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/28271686","citation_count":11,"is_preprint":false},{"pmid":"22984370","id":"PMC_22984370","title":"HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection.","date":"2012","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/22984370","citation_count":11,"is_preprint":false},{"pmid":"32435154","id":"PMC_32435154","title":"HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32435154","citation_count":11,"is_preprint":false},{"pmid":"29194801","id":"PMC_29194801","title":"Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women.","date":"2017","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/29194801","citation_count":11,"is_preprint":false},{"pmid":"26928556","id":"PMC_26928556","title":"WAP four-disulfide core domain protein 2 gene(WFDC2) is a target of estrogen in ovarian cancer cells.","date":"2016","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/26928556","citation_count":10,"is_preprint":false},{"pmid":"28117603","id":"PMC_28117603","title":"HE4-test of urine and body fluids for diagnosis of gynecologic cancer.","date":"2017","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/28117603","citation_count":10,"is_preprint":false},{"pmid":"36831601","id":"PMC_36831601","title":"Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36831601","citation_count":10,"is_preprint":false},{"pmid":"32334501","id":"PMC_32334501","title":"Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?","date":"2020","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/32334501","citation_count":10,"is_preprint":false},{"pmid":"33148127","id":"PMC_33148127","title":"Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33148127","citation_count":9,"is_preprint":false},{"pmid":"35130283","id":"PMC_35130283","title":"Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/35130283","citation_count":8,"is_preprint":false},{"pmid":"28382859","id":"PMC_28382859","title":"Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers.","date":"2017","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/28382859","citation_count":8,"is_preprint":false},{"pmid":"34307173","id":"PMC_34307173","title":"Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34307173","citation_count":8,"is_preprint":false},{"pmid":"29745428","id":"PMC_29745428","title":"HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells.","date":"2018","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29745428","citation_count":8,"is_preprint":false},{"pmid":"37418798","id":"PMC_37418798","title":"Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.","date":"2023","source":"European journal of radiology","url":"https://pubmed.ncbi.nlm.nih.gov/37418798","citation_count":8,"is_preprint":false},{"pmid":"31226514","id":"PMC_31226514","title":"Ovarian carcinomas express HE4 epitopes independently of each other.","date":"2019","source":"Cancer treatment and research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31226514","citation_count":8,"is_preprint":false},{"pmid":"38077439","id":"PMC_38077439","title":"Combination of serum CST1 and HE4 for early diagnosis of endometrial cancer.","date":"2023","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/38077439","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53796,"output_tokens":5712,"usd":0.123534,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14256,"output_tokens":4828,"usd":0.09599,"stage2_stop_reason":"end_turn"},"total_usd":0.219524,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"HE4 undergoes nuclear and nucleolar translocation upon stimulation with EGF, VEGF, and insulin, and interacts with EGFR, IGF1R, and transcription factor HIF1α. This nuclear translocation is mediated by importin-4, and ivermectin (an importin inhibitor) blocks HE4/importin-4 nuclear accumulation.\",\n      \"method\": \"Co-immunoprecipitation, nuclear fractionation, live-cell imaging, pharmacological inhibition with ivermectin\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and nuclear translocation with functional consequence shown, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24389815\", \"24975515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HE4 interacts with estrogen receptor-α (ER-α), and HE4 overexpression results in ER-α downregulation in vitro. 17β-estradiol, tamoxifen, and fulvestrant induce nuclear and nucleolar translocation of HE4, and HE4 overexpression induces resistance to antiestrogens.\",\n      \"method\": \"Co-immunoprecipitation, western blot, cell viability assays, immunofluorescence\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional rescue, single lab, two orthogonal methods\",\n      \"pmids\": [\"24975515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HE4 overexpression promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells by suppressing cisplatin-mediated upregulation of EGR1 (a MAPK-regulated pro-apoptotic gene) and suppressing p38 MAPK activation. Recombinant HE4 treatment dramatically affected ERK activation. HE4 also upregulated α-tubulin and β-tubulin levels and increased MAPT gene expression. CRISPR/Cas-mediated knockdown of HE4 partially reversed chemoresistance.\",\n      \"method\": \"MTS assays, western blot, microarray, qRT-PCR, CRISPR/Cas knockdown, treatment with recombinant HE4\",\n      \"journal\": \"Journal of ovarian research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KD with functional rescue plus microarray validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"27184254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HE4 overexpression activates the NF-κB pathway through phosphorylation and nuclear translocation of the P65 subunit, which upregulates TIMP-1 and thereby inhibits MMP-2 activity, leading to reduced ECM degradation and renal fibrosis. Hypoxia induces HE4 expression in renal tubular epithelial cells via a HIF-1α/HE4/NF-κB signaling axis. Silencing HE4 inhibited hypoxia-induced ECM deposition and alleviated fibrosis in UUO mice in vivo.\",\n      \"method\": \"UUO mouse model, HK2 cell line overexpression/silencing, western blot, phosphorylation assay, MMP-2 activity assay, immunofluorescence\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO and in vitro mechanistic studies with pathway validation, single lab, multiple methods\",\n      \"pmids\": [\"31909536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"WFDC2 binds to the extracellular domain of EGFR (shown by co-immunoprecipitation and co-localization). Overexpression of WFDC2 or addition of recombinant HE4 inactivates the EGFR/AKT/GSK3B/Snail signaling pathway and restrains epithelial-mesenchymal transition (EMT), suppressing prostate cancer metastasis.\",\n      \"method\": \"Co-immunoprecipitation, co-localization assay, immunoblot, in vivo and in vitro metastasis assays, recombinant protein addition\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and co-localization plus functional pathway validation, single lab\",\n      \"pmids\": [\"32678075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"WFDC2 contributes to ovarian cancer EMT by activating the AKT signaling pathway and inducing MMP-2 expression. Knockdown of WFDC2 suppresses EMT (upregulation of E-cadherin, downregulation of Vimentin) and decreases MMP-2. The EMT phenotype and invasion induced by WFDC2 overexpression can be reversed by siMMP-2 and PI3K/AKT signaling inhibitor.\",\n      \"method\": \"siRNA knockdown, overexpression constructs, western blot, in vivo xenograft, PI3K/AKT inhibitor rescue\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD/OE with pharmacological rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31118763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Knockdown of HE4 inhibits the JAK/STAT3 pathway in ovarian cancer cells, suppressing proliferation, invasion, and migration, and reducing MMP-2/MMP-9 levels and EMT markers in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown, western blot, flow cytometry, xenograft model\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with defined pathway readout in vitro and in vivo, single lab\",\n      \"pmids\": [\"31477564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HE4 forms a triple protein complex with ANXA2 (Annexin A2) and MMP2, co-localizing in the cytoplasm and membrane. HE4 mediates MMP2 expression via ANXA2 (acting as a 'bridge') to promote cancer cell migration.\",\n      \"method\": \"Co-immunoprecipitation, double-labeling immunofluorescence, Transwell assay, scratch test\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus co-localization showing ternary complex, single lab\",\n      \"pmids\": [\"31210752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HE4 activates STAT3 signaling and promotes upregulation of pro-angiogenic STAT3 target genes IL8 and HIF1A in immune cells, ovarian cancer cells, and endothelial cells. HE4 promoted tube formation in an in vitro angiogenesis model in a STAT3-dependent manner.\",\n      \"method\": \"Gene expression analysis, in vitro tube formation assay, western blot, STAT3 pathway inhibition, patient sample correlation\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional angiogenesis assay with STAT3 pathway validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32444701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HE4 promotes PD-L1 expression in tumor cells and macrophages through a novel posttranscriptional mechanism; high tumoral HE4 promotes an ascites cytokine profile rich in myeloid-recruiting factors, influx of M2 macrophages, increased arginase 1, and reduced CTL activation and NK cell recruitment.\",\n      \"method\": \"Syngeneic rat tumor model with HE4 high/low cancer cells, cytokine profiling, flow cytometry, retrospective patient sample analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo syngeneic model plus patient sample correlation, single lab\",\n      \"pmids\": [\"33903172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"WFDC2 promotes spasmolytic polypeptide-expressing metaplasia (SPEM) in mouse stomach by upregulating IL-33 expression in injured mucosa, which induces M2 macrophage polarization. Wfdc2-knockout mice are resistant to SPEM development. Supplementation of recombinant WFDC2 induces IL-33 production and SPEM.\",\n      \"method\": \"Wfdc2-knockout mice, three SPEM induction models (DMP-777, L635, tamoxifen), transcriptomic analysis, recombinant WFDC2 supplementation\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO replicated across three independent SPEM models plus recombinant protein rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34116028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"WFDC2 (Wfdc2) knockout mice die neonatally from respiratory failure due to increased apoptosis in type-I alveolar cells, causing hypovascular lung tissue and severe dyspnea. Wfdc2 is required for normal lung organogenesis.\",\n      \"method\": \"TALEN-based gene deletion in mice, histopathology, apoptosis assays on lung tissue\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with specific cellular phenotype (type-I alveolar apoptosis), single lab\",\n      \"pmids\": [\"31780266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Wfdc2-null mice display progressive atelectasis at birth with impaired cilia, absence of mature club cells from tracheo-bronchial airways, and malformed lamellar bodies in type II alveolar epithelial cells. RNA sequencing shows significant activation of a pro-inflammatory pathway in mutant lungs.\",\n      \"method\": \"Wfdc2-GFP knock-in and null-mutant mouse lines, histopathology, RNA sequencing, immunofluorescence\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic null mice with multiple defined cellular phenotypes and transcriptomic validation, independently generated mouse line from separate lab\",\n      \"pmids\": [\"31562139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Biallelic pathogenic variants in WFDC2 cause nasal polyposis and bronchiectasis in humans. WFDC2 is expressed in secretory cells of airway epithelium and submucosal glands. A founder variant p.Cys49Arg structurally hampers glycosylation and thereby blocks secretion of mature WFDC2, confirming that secretion is required for normal airway function.\",\n      \"method\": \"Next-generation and Sanger sequencing, Western blotting, immunofluorescence microscopy, deglycosylation assays, computer simulations of protein structure, electrochemiluminescence immunoassay of serum\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — human genetic disease identified in 10 unrelated families with biochemical confirmation of glycosylation/secretion defect by deglycosylation assay and structural modeling\",\n      \"pmids\": [\"38626355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CFTR dysfunction contributes to elevated HE4 expression via the NF-κB pathway in cystic fibrosis bronchial epithelial cells. CFTR modulators (lumacaftor/ivacaftor, tezacaftor/ivacaftor) partially restored CFTR activity and reduced HE4 secretion. TNF-α upregulated HE4 through NF-κB (p65 nuclear translocation), and NF-κB inhibitor BAY 11-7082 suppressed HE4 expression.\",\n      \"method\": \"CFBE cell line transfected with F508del-CFTR or wt-CFTR, whole-cell patch-clamp, immunoassay, fluorescence microscopy for p65 translocation, pharmacological inhibition\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patch-clamp-validated CFTR modulation correlated with HE4 expression plus NF-κB pathway mechanistic validation, single lab\",\n      \"pmids\": [\"34054511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC3 interacts with HE4 protein (identified as an HDAC3-interacting protein). HDAC3 promotes ovarian carcinoma cell proliferation, invasion, and migration by increasing HE4 expression, and this axis activates the PI3K/AKT signaling pathway (elevated P-PI3K and P-AKT).\",\n      \"method\": \"Co-immunoprecipitation (HDAC3-HE4 interaction), immunohistochemistry, western blot, wound healing assay, Transwell assay, CCK8 proliferation assay, siRNA knockdown\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP for interaction, functional assays show PI3K/AKT pathway activation, single lab\",\n      \"pmids\": [\"31302139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HE4 suppresses osteopontin (OPN) expression in peripheral blood mononuclear cells (PBMCs) and compromises their cytotoxicity against ovarian cancer cells. SKOV3 and OVCAR8 cells showed enhanced proliferation in conditioned media from HE4-exposed PBMCs, an effect attenuated by recombinant OPN or OPN-inducible cytokines (IL-12 and IFN-γ). HE4-silenced SKOV3 cells were more susceptible to cytotoxic cell death upon co-culture with PBMCs.\",\n      \"method\": \"Subtractive hybridization, PBMC co-culture, conditioned media experiments, recombinant OPN rescue, siRNA knockdown of HE4, patient biopsy correlation\",\n      \"journal\": \"Clinical and experimental immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene expression profiling with functional rescue and KD validation, single lab, multiple methods\",\n      \"pmids\": [\"29745428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HE4 overexpression in endometrial cancer cell lines significantly enhanced cell proliferation, matrigel invasion, and colony formation in soft agar, and promoted tumor growth in a mouse xenograft model, establishing a direct role for HE4 in tumor progression.\",\n      \"method\": \"Stable transfection of HE4-V0 expression construct, cell proliferation assay, matrigel invasion assay, soft agar colony formation, mouse xenograft model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable overexpression with in vivo xenograft validation, single lab, multiple orthogonal cellular assays\",\n      \"pmids\": [\"23502467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Recombinant extracellular HE4 protein promotes proliferation of pancreatic and endometrial cancer cell lines, increases DNA synthesis, and modulates cell cycle markers PCNA (upregulated) and p21 (downregulated) at mRNA and protein levels.\",\n      \"method\": \"Cell viability assay (CCK-8), BrdU incorporation, western blot, qRT-PCR with purified recombinant HE4 protein\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — recombinant protein treatment with defined molecular readouts, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"25354091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HE4 secreted from HE4-transfected HEK293T cells activates ERK signaling in cardiac fibroblasts and promotes their transdifferentiation, increasing expression of fibrosis-related genes. Treatment with an ERK upstream inhibitor or a neutralizing HE4 antibody canceled the profibrotic properties of HE4.\",\n      \"method\": \"HEK293T transfection, conditioned media treatment of rat neonatal cardiac fibroblasts, western blot for ERK signaling, fibrosis gene expression, neutralizing antibody rescue\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditioned media experiment with pathway rescue by neutralizing antibody and inhibitor, single lab\",\n      \"pmids\": [\"34320813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"High-dose estradiol (E2) increases WFDC2 expression in estrogen-sensitive HO8910 ovarian cancer cells, but not in estrogen-insensitive SKOV3 cells. Knockdown of WFDC2 in SKOV3 cells confers estrogen responsiveness (proliferative response to E2), accompanied by upregulation of estrogen receptor beta (ERβ).\",\n      \"method\": \"RT-PCR, western blot, MTT proliferation assay, flow cytometry for ER expression, annexin V/PI apoptosis assay, antibody array\",\n      \"journal\": \"Journal of ovarian research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD functional rescue plus multi-method characterization, single lab\",\n      \"pmids\": [\"26928556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In tammar wallaby, WFDC2 protein (comprising two 4-DSC domains: domain III at N-terminus and domain II at C-terminus) demonstrates antibacterial activity against Staphylococcus aureus, Salmonella enterica, and Pseudomonas aeruginosa, with this activity residing specifically in domain II. No antibacterial activity was detected against Enterococcus faecalis.\",\n      \"method\": \"Recombinant protein expression, antibacterial activity assays with individual domains, gene expression profiling during lactation\",\n      \"journal\": \"Developmental and comparative immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro biochemical activity assay with domain mapping, single lab, marsupial ortholog\",\n      \"pmids\": [\"22024352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HE4 is a secreted glycoprotein; conditioned media from ovarian cancer cell lines that endogenously overexpress HE4 revealed a secreted, N-glycosylated form of the protein.\",\n      \"method\": \"RT-PCR identification of HE4-expressing cell lines, conditioned medium analysis, N-glycosylation characterization\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical characterization of secreted glycoprotein, replicated across multiple groups\",\n      \"pmids\": [\"15781627\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"WFDC2/HE4 is a small, secreted, N-glycosylated WAP-domain protein that functions extracellularly and, following nuclear translocation via importin-4, intracellularly: it binds EGFR's extracellular domain and ER-α, activates downstream EGFR/AKT/GSK3B/Snail and PI3K/AKT/MMP-2 signaling to promote EMT and metastasis, activates STAT3 to drive pro-angiogenic and immunosuppressive gene programs, suppresses p38/MAPK-mediated apoptotic signaling to confer chemoresistance, activates NF-κB (via p65 phosphorylation and nuclear translocation) to promote fibrosis and ECM accumulation, forms a ternary complex with ANXA2 and MMP-2 to facilitate cell migration, and in the lung is essential for neonatal alveolar function (type-I alveolar cell survival, club cell maturation, and lamellar body formation), with loss-of-function mutations in humans causing bronchiectasis and nasal polyposis due to impaired glycosylation and secretion of the mature protein.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"WFDC2 (HE4) is a small, secreted, N-glycosylated WAP-domain protein that acts as an extracellular signaling ligand controlling epithelial homeostasis, tissue remodeling, and tumor progression [#22, #4]. Its biology centers on engagement of cell-surface receptors and activation of downstream signaling: WFDC2 binds the extracellular domain of EGFR and, depending on context, modulates EGFR/AKT/GSK3B/Snail signaling and epithelial-mesenchymal transition [#4], while in ovarian cancer it drives EMT and invasion through PI3K/AKT-dependent induction of MMP-2 [#5] and activation of JAK/STAT3 signaling [#6]. WFDC2 also forms a cytoplasmic and membrane-associated ternary complex with ANXA2 and MMP-2, using ANXA2 as a bridge to promote migration [#7]. Beyond canonical surface signaling, WFDC2 undergoes importin-4-mediated nuclear and nucleolar translocation upon EGF, VEGF, insulin, or estrogen stimulation and interacts with EGFR, IGF1R, HIF1\\u03b1, and ER-\\u03b1 [#0, #1]. WFDC2 shapes the tumor and tissue microenvironment by activating STAT3 to induce pro-angiogenic genes (IL8, HIF1A) [#8] and by fostering immunosuppression through PD-L1 induction, M2 macrophage recruitment, and suppression of cytotoxic lymphocyte activity [#9, #16]. A recurring fibrotic and inflammatory axis operates through NF-\\u03baB: WFDC2 activates p65 phosphorylation and nuclear translocation to drive ECM accumulation and renal fibrosis via TIMP-1/MMP-2 [#3], promotes IL-33-dependent gastric metaplasia and M2 polarization [#10], and is itself induced by TNF-\\u03b1 and CFTR dysfunction through NF-\\u03baB [#14]. In vivo, Wfdc2 is essential for neonatal lung function: knockout mice die from respiratory failure with type-I alveolar cell apoptosis, absent mature club cells, malformed lamellar bodies, and aberrant pro-inflammatory activation [#11, #12]. Biallelic loss-of-function variants in WFDC2 cause human nasal polyposis and bronchiectasis, with a founder p.Cys49Arg substitution that disrupts glycosylation and blocks secretion of the mature protein, establishing that secretion is required for normal airway function [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established the basic biochemical identity of HE4 as a secreted, N-glycosylated protein, defining it as an extracellular factor rather than an intracellular enzyme.\",\n      \"evidence\": \"Conditioned-medium analysis and N-glycosylation characterization from HE4-overexpressing ovarian cancer lines\",\n      \"pmids\": [\"15781627\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No receptor or binding partner identified\", \"Function of the secreted protein not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed that HE4 is not merely a biomarker but a direct driver of tumor progression, motivating mechanistic dissection of its signaling.\",\n      \"evidence\": \"Stable HE4 overexpression with proliferation, invasion, soft-agar colony and xenograft assays in endometrial cancer cells\",\n      \"pmids\": [\"23502467\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor and downstream pathway unresolved\", \"Single tumor type\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed an unexpected intracellular dimension by showing growth-factor- and estrogen-stimulated importin-4-dependent nuclear/nucleolar translocation and interactions with EGFR, IGF1R, HIF1\\u03b1 and ER-\\u03b1, plus a role in antiestrogen resistance.\",\n      \"evidence\": \"Co-IP, nuclear fractionation, live-cell imaging, ivermectin inhibition, and viability assays in cancer cells\",\n      \"pmids\": [\"24389815\", \"24975515\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear function of HE4 (transcriptional or otherwise) not defined\", \"Direct vs. indirect nature of receptor interactions unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that extracellular recombinant HE4 alone is mitogenic and modulates cell-cycle regulators, confirming a ligand-like proliferative activity.\",\n      \"evidence\": \"Recombinant HE4 treatment with BrdU, CCK-8, and PCNA/p21 readouts in pancreatic and endometrial lines\",\n      \"pmids\": [\"25354091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating the proliferative effect not identified\", \"Signaling cascade not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked HE4 to chemoresistance by showing it suppresses p38/ERK-MAPK pro-apoptotic signaling and the pro-apoptotic gene EGR1.\",\n      \"evidence\": \"Recombinant HE4 and CRISPR knockdown with MTS, microarray, and western blot in ovarian cancer cells\",\n      \"pmids\": [\"27184254\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular target upstream of MAPK not defined\", \"Tubulin/MAPT effects mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Assembled a coherent pro-metastatic signaling network, defining PI3K/AKT-MMP-2-driven EMT, JAK/STAT3 activation, an HDAC3-HE4-PI3K/AKT axis, and an ANXA2-MMP-2 ternary complex.\",\n      \"evidence\": \"siRNA/overexpression with pharmacological rescue, Co-IP, immunofluorescence, and xenografts across ovarian cancer studies\",\n      \"pmids\": [\"31118763\", \"31477564\", \"31302139\", \"31210752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether AKT and STAT3 arms are parallel or sequential is unresolved\", \"Direct receptor for HE4 in these pathways not pinpointed\", \"ANXA2 interaction shown by single-lab Co-IP\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established WFDC2 as essential for neonatal lung development, providing the first in vivo loss-of-function phenotype and shifting the picture from cancer ligand to developmental regulator.\",\n      \"evidence\": \"TALEN and null/GFP knock-in mouse lines from independent labs with histopathology, apoptosis assays, and RNA-seq\",\n      \"pmids\": [\"31780266\", \"31562139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism connecting WFDC2 loss to alveolar/club-cell defects not defined\", \"Receptor mediating the developmental role unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified an NF-\\u03baB/TIMP-1/MMP-2 axis driving fibrosis, showing HE4 restrains ECM degradation downstream of HIF-1\\u03b1.\",\n      \"evidence\": \"UUO mouse model and HK2 overexpression/silencing with phosphorylation and MMP-2 activity assays\",\n      \"pmids\": [\"31909536\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How secreted HE4 activates intracellular NF-\\u03baB is unresolved\", \"Receptor not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided reciprocal evidence that WFDC2 binds the EGFR extracellular domain and, in prostate cancer, can suppress EGFR/AKT/GSK3B/Snail-driven EMT, indicating context-dependent (suppressive vs. promoting) outputs.\",\n      \"evidence\": \"Reciprocal Co-IP, co-localization, recombinant protein, and metastasis assays in prostate cancer\",\n      \"pmids\": [\"32678075\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reason for opposite EMT outcomes between tumor types unexplained\", \"Stoichiometry and affinity of EGFR binding not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended HE4 function to the microenvironment by showing STAT3-dependent induction of pro-angiogenic IL8 and HIF1A and promotion of endothelial tube formation.\",\n      \"evidence\": \"Gene expression, tube-formation assay, STAT3 inhibition, and patient correlation\",\n      \"pmids\": [\"32444701\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor coupling HE4 to STAT3 not defined\", \"In vivo angiogenic contribution not directly tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined HE4 as an immunosuppressive factor, inducing PD-L1, recruiting M2 macrophages, and dampening cytotoxic lymphocyte activity, partly via suppression of osteopontin.\",\n      \"evidence\": \"Syngeneic rat tumor model, cytokine profiling, flow cytometry, PBMC co-culture with OPN rescue, and patient samples\",\n      \"pmids\": [\"33903172\", \"29745428\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Posttranscriptional mechanism of PD-L1 induction undefined\", \"Direct vs. indirect action on immune cells unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Broadened the inflammatory/fibrotic role across organs, showing WFDC2 drives IL-33-dependent gastric metaplasia, ERK-dependent cardiac fibroblast transdifferentiation, and is induced by CFTR dysfunction via NF-\\u03baB.\",\n      \"evidence\": \"Wfdc2-knockout mice with three SPEM models and recombinant rescue, conditioned-media cardiac fibroblast assays with neutralizing antibody, and CFBE patch-clamp/NF-\\u03baB studies\",\n      \"pmids\": [\"34116028\", \"34320813\", \"34054511\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor transducing the profibrotic/metaplastic signal not identified\", \"Whether NF-\\u03baB induction of HE4 and HE4 activation of NF-\\u03baB form a feedback loop is untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected WFDC2 to a human Mendelian disease, showing biallelic loss-of-function causes nasal polyposis and bronchiectasis through a glycosylation/secretion defect, validating that mature secreted protein is required for airway function.\",\n      \"evidence\": \"Sequencing in 10 families, deglycosylation assays, western blot, immunofluorescence, and structural modeling of the p.Cys49Arg founder variant\",\n      \"pmids\": [\"38626355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of secreted WFDC2 in the airway not identified\", \"How loss leads to polyposis vs. bronchiectasis not dissected\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The central unresolved question is the identity and stoichiometry of the bona fide WFDC2 receptor(s) that transduce its many context-dependent outputs (EGFR/AKT, STAT3, NF-\\u03baB, ERK), and the molecular basis of its opposite roles across tissues and tumor types.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying receptor model across the documented pathways\", \"Mechanism reconciling tumor-promoting and tumor-suppressing EMT effects unknown\", \"Biochemical function of nuclear-localized WFDC2 undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [4, 18, 5, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 3, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [22, 13]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 6, 8, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 3, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 12]}\n    ],\n    \"complexes\": [\n      \"WFDC2-ANXA2-MMP2 ternary complex\"\n    ],\n    \"partners\": [\n      \"EGFR\",\n      \"IGF1R\",\n      \"HIF1A\",\n      \"ESR1\",\n      \"ANXA2\",\n      \"MMP2\",\n      \"HDAC3\",\n      \"IPO4\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":8,"faith_total":8,"faith_pct":100.0}}